PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers.

This study is the first to compare the SP142 antibody in bladder cancer on two different stainers. Our results indicate that both Benchmark Ultra and Bond-III stainers yield highly concordant results using the SP142 PD-L1 antibody.